Management of colorectal peritoneal metastases: Expert opinion.
暂无分享,去创建一个
M. Ychou | M. Ducreux | M. Pocard | O. Sgarbura | P. Mariani | C. Eveno | J. Lefèvre | T. André | F. Quénet | D. Goéré | J. Gornet | K. Abboud | O. Glehen | A. Pinto | M. Brunel
[1] W. Ceelen. HIPEC with oxaliplatin for colorectal peritoneal metastasis: The end of the road? , 2019, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[2] B. Rau,et al. Cytoreductive Surgery (CRS) and Hyperthermic IntraPeritoneal Chemotherapy (HIPEC): don’t throw the baby out with the bathwater , 2018, Pleura and Peritoneum.
[3] S. Évrard,et al. [Autopsy of an expert consensus. To end hyperthermic intraperitoneal chemotherapy in colorectal carcinomatosis]. , 2018, Bulletin du cancer.
[4] M. Pocard,et al. A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7. , 2018, Journal of Clinical Oncology.